← Back to Search

Overdose Prevention Strategies for Substance Use Disorders (FORTRESS Trial)

N/A
Waitlist Available
Led By Matthew C Aalsma, PhD
Research Sponsored by Indiana University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through study completion, an average of 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial seeks to equip overdose fatality review teams with data tools & training to help identify opportunities to prevent overdose deaths & support evidence-based prevention strategies.

Who is the study for?
This trial is for members of local overdose fatality review (OFR) teams or leaders in Indiana organizations involved with OFR, such as public jail administrators and health directors. It also includes residents of Indiana who have had fatal or non-fatal overdoses.
What is being tested?
The FORTRESS project aims to improve how OFR teams work by giving them a data dashboard and training in Data-Driven Decision Making (DDDM). The study will compare these new tools against standard practices to see if they can better prevent overdoses.
What are the potential side effects?
Since this trial focuses on improving data systems and decision-making processes rather than medical interventions, it does not involve typical clinical side effects.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through study completion, an average of 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through study completion, an average of 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cultural Exchange Inventory (adapted to evaluate OFR team alliance)
Dashboard Aggregate Usage
Harm reduction acceptability scale
+8 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: FORTRESSExperimental Treatment2 Interventions
Participating counties receive both training in data-driven decision making and inventory of overdose-prevention strategies
Group II: OFR Team Practice as UsualActive Control1 Intervention
Data are collected regarding standard OFR Team practice and outcomes before implementation of the FORTRESS Intervention

Find a Location

Who is running the clinical trial?

National Institute on Drug Abuse (NIDA)NIH
2,586 Previous Clinical Trials
3,328,136 Total Patients Enrolled
Indiana UniversityLead Sponsor
1,039 Previous Clinical Trials
1,218,658 Total Patients Enrolled
Matthew C Aalsma, PhDPrincipal InvestigatorIndiana University School of Medicine
1 Previous Clinical Trials
400 Total Patients Enrolled
~267 spots leftby Sep 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top